Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC

Inclusion Criteria: * Patients must have histologically or cytologically confirmed, newly diagnosed Stage IIIB, stage IV, or recurrent non-squamous NSCLC for which they have not received chemotherapy. * Patients must have completed radiation therapy 2 weeks prior to enrollment. Patients may have received adjuvant therapy, provided the regimen included no more than one of the study agents. * Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension. * Age \>18 years. •Life expectancy of greater than 4 months. * ECOG performance status of 0 or 1 * Patients must have normal organ and marrow function * Patients on anticoagulation are allowed. * Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: Disease-Specific * Patients who have had received prior chemotherapy (in the setting of recurrent disease, other than their original adjuvant therapy) * Patients may not be receiving any other investigational agents. * Patients with histologic evidence of predominantly squamous lung cell cancer * General Medical Exclusions * Inability to comply with study and/or follow-up procedures * Malignancy other than superficial basal cell and superficial squamous of the skin or carcinoma in situ of the cervix within last five years Bevacizumab-Specific Exclusions * Inadequately controlled hypertension * Prior history of hypertensive crisis or hypertensive encephalopathy * New York Heart Association Grade II or greater congestive heart failure * History of myocardial infarction or unstable angina within 6 months prior to Day 1 * History of stroke or transient ischemic attack within 6 months prior to Day 1 * Known CNS disease, except for treated brain metastasis. * Significant vascular disease within 6 months prior to Day 1 * History of hemoptysis within 1 month prior to Day 1 * Evidence of bleeding diathesis or significant coagulopathy * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during the course of the study * Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1 * History of diverticulitis, abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1 * Serious, non-healing wound, active ulcer, or untreated bone fracture * Proteinuria as demonstrated by a UPC ratio 1.0 at screening * Known hypersensitivity to any component of bevacizumab * Pregnancy (positive pregnancy test) or lactation. * Mixed tumors will be categorized by the predominant cell type unless small cell elements are present. * Uncontrolled intercurrent illness including, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements. * Any unstable condition that in the opinion of the investigator is likely to interfere with collection of accurate blood pressure measurement data . * HIV-positive patients on combination antiretroviral therapy.